Steven Narod

Summary

Affiliation: Sunnybrook and Women's College Health Sciences Centre
Country: Canada

Publications

  1. pmc The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
    S R Young
    Women s College Research Institute, Department of Public Health, The University of Toronto, Toronto, Canada
    BMC Cancer 9:86. 2009
  2. pmc Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors
    Darren R Brenner
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, 60 Murray St, Toronto M5T3L9, Canada
    BMC Cancer 10:285. 2010
  3. ncbi Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group
    S A Narod
    Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Lancet 356:1876-81. 2000
  4. ncbi Modifiers of risk of hereditary breast and ovarian cancer
    Steven A Narod
    Centre for Research on Women s Health, Women s College Hospital, 790 Bay Street, Room 750, University of Toronto, Toronto, Canada M5G 1N8
    Nat Rev Cancer 2:113-23. 2002
  5. pmc Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
    Kelly A Metcalfe
    The Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
    Hered Cancer Clin Pract 3:53-7. 2005
  6. ncbi Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Steven A Narod
    The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    J Natl Cancer Inst 94:1773-9. 2002
  7. pmc The prevention of hereditary breast and ovarian cancer: a personal view
    Steven Narod
    Centre for Research on Women s Health, University of Toronto, Toronto, Ontario, Canada
    Hered Cancer Clin Pract 2:5-10. 2004
  8. ncbi Method of cooking and risk of breast cancer in the Philippines
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Cancer Causes Control 17:341-8. 2006
  9. ncbi What options for treatment of hereditary breast cancer?
    Steven Narod
    Centre for Research on Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON M5G 1N8, Canada
    Lancet 359:1451-2. 2002
  10. ncbi Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
    S A Narod
    Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Room 750, M5G 1N8, Ontario, Canada
    Lancet 357:1467-70. 2001

Detail Information

Publications112 found, 100 shown here

  1. pmc The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
    S R Young
    Women s College Research Institute, Department of Public Health, The University of Toronto, Toronto, Canada
    BMC Cancer 9:86. 2009
    ....
  2. pmc Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors
    Darren R Brenner
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, 60 Murray St, Toronto M5T3L9, Canada
    BMC Cancer 10:285. 2010
    ....
  3. ncbi Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group
    S A Narod
    Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Lancet 356:1876-81. 2000
    ..Tamoxifen protects against contralateral breast cancer in the general population, but whether it protects against contralateral breast cancer in BRCA1 or BRCA2 mutation carriers is not known...
  4. ncbi Modifiers of risk of hereditary breast and ovarian cancer
    Steven A Narod
    Centre for Research on Women s Health, Women s College Hospital, 790 Bay Street, Room 750, University of Toronto, Toronto, Canada M5G 1N8
    Nat Rev Cancer 2:113-23. 2002
    ..Genetic risk can be modified by external factors, but what are these factors, and how might our knowledge of them help us to better define the risks for individual women and to develop strategies for cancer prevention?..
  5. pmc Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
    Kelly A Metcalfe
    The Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Canada
    Hered Cancer Clin Pract 3:53-7. 2005
    ..To compare the presentation of invasive breast cancer in BRCA1 and BRCA2 mutation carriers with and without prior bilateral oophorectomy...
  6. ncbi Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Steven A Narod
    The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    J Natl Cancer Inst 94:1773-9. 2002
    ..We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2...
  7. pmc The prevention of hereditary breast and ovarian cancer: a personal view
    Steven Narod
    Centre for Research on Women s Health, University of Toronto, Toronto, Ontario, Canada
    Hered Cancer Clin Pract 2:5-10. 2004
    ..Oral contraceptives and tubal ligation will reduce the risk of hereditary ovarian cancer and should be considered in women who wish to retain ovarian function...
  8. ncbi Method of cooking and risk of breast cancer in the Philippines
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Cancer Causes Control 17:341-8. 2006
    ..We conducted a case-control study in Manila to examine the association between methods of cooking and the risk of breast cancer...
  9. ncbi What options for treatment of hereditary breast cancer?
    Steven Narod
    Centre for Research on Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON M5G 1N8, Canada
    Lancet 359:1451-2. 2002
  10. ncbi Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
    S A Narod
    Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Room 750, M5G 1N8, Ontario, Canada
    Lancet 357:1467-70. 2001
    ..We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes...
  11. ncbi Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer
    Steven A Narod
    The Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Toronto, Canada
    Curr Opin Obstet Gynecol 14:19-26. 2002
    ..Strategies for prevention of ovarian cancer among carriers include oral contraceptives, tubal ligation and prophylactic oophorectomy...
  12. ncbi Hormonal prevention of hereditary breast cancer
    S A Narod
    The Centre for Research on Women s Health, Women s College Hospital, University of Toronto, Ontario, Canada
    Ann N Y Acad Sci 952:36-43. 2001
    ..There are no data so far on whether hormonal replacement therapy is hazardous in carriers of BRCA mutations...
  13. pmc Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Alexander Liede
    University of Toronto, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Am J Hum Genet 71:595-606. 2002
    ..7; 95% CI 1.5-4.9; P=.0008) and case subjects with ovarian cancer (OR=2.4; 95% CI 1.4-4.2; P=.002). These results suggest that recessively inherited genes may contribute to breast and ovarian cancer risk in Pakistan...
  14. ncbi A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations
    Mary Jane Esplen
    Behavioral Sciences and Health Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Cancer 101:2327-40. 2004
    ..The current study developed, standardized, and conducted preliminary testing of a supportive-expressive group therapy intervention designed to address these challenges...
  15. ncbi Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
    John R McLaughlin
    Samuel Lunenfeld Research Institute, Toronto, ON, Canada
    Lancet Oncol 8:26-34. 2007
    ..We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes...
  16. ncbi Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study
    Andrea Eisen
    Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada
    J Clin Oncol 23:7491-6. 2005
    ....
  17. ncbi Use of alternative therapy in postmenopausal breast cancer patients treated with tamoxifen after surgery
    Karen P L Yap
    Department of Surgical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    Breast J 10:481-6. 2004
    ..In conclusion, 27% of patients with early stage breast cancer used alternative therapy. Users were more likely to be younger and to experience shoulder or arm symptoms after breast-conserving surgery with radiation...
  18. ncbi The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, 50 St George Street, Toronto, Ontario, Canada
    Fam Cancer 4:97-103. 2005
    ....
  19. ncbi Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada
    Breast Cancer Res Treat 105:221-8. 2007
    ..Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective...
  20. ncbi The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, 50 St George Street, Toronto, ON, Canada, M5S 3H4
    Gynecol Oncol 96:222-6. 2005
    ..To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk...
  21. ncbi Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, University of Toronto, Women s College Hospital, 790 Bay Street, 7th Floor, Totonto, Ontario M5G 1N8, Canada
    Cancer Causes Control 16:667-74. 2005
    ..46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation...
  22. pmc Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update
    Ophira Ginsburg
    The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 114:127-35. 2009
    ..There is a possibility of an increased risk of breast cancer among BRCA1 carriers associated with past smoking. There may be different effects of carcinogens in BRCA mutation carriers, depending upon the timing of exposure...
  23. ncbi Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1N8
    Gynecol Oncol 100:83-8. 2006
    ..This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers...
  24. doi Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation
    Amy Finch
    Familial Breast Cancer Research, Women s College Research Institute Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Fertil Steril 99:1724-8. 2013
    ..To evaluate the impact of carrying a BRCA1 or BRCA2 mutation on the probability of experiencing premature natural menopause...
  25. ncbi An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers
    Jordana Segal
    Department of Psychiatry, Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Med Genet A 125:267-72. 2004
    ..Both disclosed and non-disclosed carriers demonstrated significant interest in a variety of interventions to support the disclosure process...
  26. ncbi Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Kelly Metcalfe
    Centre for Research on Women s Health, Women s College Hospital, Toronto, Ontario, Canada
    J Clin Oncol 22:2328-35. 2004
    ..To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers after diagnosis and to determine which factors are predictive of the risk of a second primary breast cancer...
  27. ncbi Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination
    Ellen Warner
    Division of Medical Oncology, Department of Medicine, Sunnybrook and Women s College Health Sciences Centre and University of Toronto, Ontario, Canada
    JAMA 292:1317-25. 2004
    ..Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage...
  28. ncbi Prevention and management of hereditary breast cancer
    Steven A Narod
    Centre for Research in Women s Health, University of Toronto, 790 Bay St, Toronto, Ontario M5G 1N8, Canada
    J Clin Oncol 23:1656-63. 2005
  29. ncbi Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
    Steven A Narod
    Centre for Research on Women s Health, University of Toronto, Ontario, Canada
    Lancet Oncol 7:402-6. 2006
    ..We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers...
  30. ncbi Towards a dietary prevention of hereditary breast cancer
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Toronto, Ontario, Canada
    Cancer Causes Control 16:125-38. 2005
    ..The prevention of hereditary breast cancer through diet is an attractive complement to current management strategies and deserves exploration...
  31. doi Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group
    Kelly A Metcalfe
    Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada
    J Clin Oncol 26:1093-7. 2008
    ..To evaluate the rate of prophylactic contralateral mastectomy in an international cohort of women with hereditary breast cancer and to evaluate the predictors of uptake of preventive surgery...
  32. ncbi Mutations of the MYH gene do not substantially contribute to the risk of breast cancer
    Mario E Beiner
    Women s College Research Institute, Women s College Hospital, 790 Bay Street, 7th Floor, Toronto, ON, Canada M5G 1N8
    Breast Cancer Res Treat 114:575-8. 2009
    ..To explore whether or not there is an association between the presence of either of the germline mutations in the MutY human homologue (MYH) gene (Y165C and G382D) and the risk of breast cancer...
  33. pmc Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Breast Cancer Res 7:R833-43. 2005
    ..We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2...
  34. pmc Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
    Andrea Eisen
    Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    J Natl Cancer Inst 100:1361-7. 2008
    ....
  35. doi Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Cancer Causes Control 19:1111-9. 2008
    ..It is important to evaluate whether or not infertility per se or exposure to fertility medications increase the risk of breast cancer in genetically predisposed women...
  36. ncbi Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy
    Eileen Rakovitch
    Toronto Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    J Clin Oncol 25:5591-6. 2007
    ..The objective of this study is to evaluate the significance of multifocality and the outcomes of women with multifocal DCIS treated with breast-conserving therapy...
  37. ncbi Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy
    Terence J Colgan
    Department of Laboratory Medicine and Pathology, Mount Sinai Hospital, Toronto, Canada
    Gynecol Oncol 85:397-403. 2002
    ..This study sought to assess the utility of peritoneal lavage cytology at the time of PO in detecting occult malignancy in this group of patients...
  38. ncbi Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran
    Mohammad Reza Akbari
    Institute of Medical Science, Faculty of Medicine, University of Toronto, Canada
    Int J Cancer 119:1047-51. 2006
    ..The hazard ratio of 2.3 for cancer among first-degree relatives is consistent with an important contribution of heritable factors. It will be of interest to perform marker studies to establish which genes are responsible...
  39. ncbi A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families
    Catherine M Phelan
    Center for Research in Women s Health, Toronto, Ontario, Canada
    Hum Mutat 20:352-7. 2002
    ..Non-founder BRCA1 mutations are rare in Ashkenazi Jewish breast/ovarian cancer families...
  40. pmc International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
    Kelly A Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
    Int J Cancer 122:2017-22. 2008
    ..Approximately one-half of women at risk for breast cancer rely on screening alone...
  41. ncbi A BRCA1 mutation in Native North American families
    Alexander Liede
    University of Toronto and Sunnybrook and Women s College, Health Sciences Centre, Toronto, Canada
    Hum Mutat 19:460. 2002
    ..The families represent two aboriginal Canadian tribes (Cree and Ojibwe), although a common ancestral origin is likely. This is the first evidence of a BRCA1 mutation specific to aboriginal peoples of North America...
  42. ncbi Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
    Amy Finch
    The Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Toronto, ON, Canada M5G 1N8
    Gynecol Oncol 100:58-64. 2006
    ..To estimate the likelihood of occult cancer diagnosis at prophylactic oophorectomy in BRCA1 and BRCA2 carriers in different age groups and to determine the histopathology of these lesions...
  43. ncbi Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers
    Danielle Vicus
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada
    Gynecol Oncol 118:295-8. 2010
    ..To identify risk factors for the presence of a non-invasive lesion of the fallopian tube in women with a BRCA1 or BRCA2 mutation...
  44. doi The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
    Ophira M Ginsburg
    Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Canada
    Fam Cancer 8:563-7. 2009
    ..No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer...
  45. pmc Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
    Danielle Vicus
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada
    Gynecol Oncol 115:135-7. 2009
    ..Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation...
  46. doi Germline RAP80 mutations and susceptibility to breast cancer
    Mohammad Reza Akbari
    Women s College Research Institute, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, Canada
    Breast Cancer Res Treat 113:377-81. 2009
    ..A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies...
  47. ncbi Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada
    David McCready
    Department of Surgery, University Health Network, Toronto, Ontario, Canada
    Cancer Causes Control 15:399-418. 2004
    ..2; 95% CI = 1.1-4.4). However, multiple comparisons were made and generally our data do not support the hypothesis that organochlorines increase the risk of breast cancer among subgroups of women with specific metabolic genotypes...
  48. ncbi A comparison of bilateral breast cancers in BRCA carriers
    Jeffrey N Weitzel
    The Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
    Cancer Epidemiol Biomarkers Prev 14:1534-8. 2005
    ..It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown...
  49. ncbi Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines
    Alexander Liede
    University of Toronto and Sunnybrook Women s College Health Sciences Centre, Toronto, Ontario M5G 1N8, Canada
    Cancer Epidemiol Biomarkers Prev 12:848-52. 2003
    ..These findings support the theory that short trinucleotide repeat genotypes of the AR gene protect against breast cancer...
  50. ncbi Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma
    Karen P L Yap
    Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Cancer 97:1369-75. 2003
    ..The purpose of the current study was to identify the factors that contribute to postoperative arm symptoms following breast conserving surgery in a well-defined cohort of node negative breast carcinoma patients...
  51. doi Is mammography adequate for screening women with inherited BRCA mutations and low breast density?
    Rachel Z Bigenwald
    Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Cancer Epidemiol Biomarkers Prev 17:706-11. 2008
    ..We sought to determine the extent to which the low sensitivity of mammography is due to greater breast density...
  52. ncbi A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene
    Graciela Kuperstein
    The Centre for Research in Women s Health, University of Toronto, Toronto, Ontario, Canada
    Genet Test 10:1-7. 2006
    ..This technique may prove to be a useful research tool for the detection of mutations and polymorphisms in the BRCA1 gene and for large-scale epidemiologic studies...
  53. ncbi The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Canada
    Cancer Epidemiol Biomarkers Prev 16:912-6. 2007
    ..This study suggests that caffeine protects against breast cancer in women with a BRCA1 mutation and illustrates the importance of integrating individual genetic variability when assessing diet-disease associations...
  54. ncbi A BRCA1 mutation is not associated with increased indicators of oxidative stress
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Ontario, Canada
    Clin Breast Cancer 8:506-10. 2008
    ..It is possible that individuals with a BRCA1 mutation might be susceptible to the effects of oxidative stress. The aim of this study was to evaluate whether women with a BRCA1 mutation exhibit increased indicators of oxidative stress...
  55. pmc Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study
    Kelly A Metcalfe
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    Gynecol Oncol 112:68-72. 2009
    ..It is unknown what proportion of women with ovarian cancer receive genetic testing as a result of this recommendation...
  56. doi Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation
    Danielle Vicus
    Women s College Research Institute, 790 Bay Street, Toronto, Ontario, Canada
    Gynecol Oncol 118:155-9. 2010
    ..The purpose of this study was to identify risk factors for fallopian tube cancer in women with and without a BRCA mutation...
  57. ncbi Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation
    Amy Finch
    Centre for Research in Women s Health, Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    JAMA 296:185-92. 2006
    ..Women with BRCA1 or BRCA2 mutation are often advised to undergo preventive oophorectomy. The effectiveness of this intervention has not been prospectively evaluated in a large cohort...
  58. ncbi Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2
    Alexander Liede
    Centre for Research in Women s Health, University of Toronto, Toronto, Ontario, Canada
    Hum Mutat 20:413-24. 2002
    ..Studies conducted on the Asian populations described here have expanded our current knowledge of genetic susceptibility and its contribution to breast and ovarian cancer rates in Asian populations...
  59. ncbi Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    Psychooncology 13:14-25. 2004
    ....
  60. ncbi Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study
    Kelly A Metcalfe
    Faculty of Nursing, University of Toronto, Ontario, Canada
    Plast Reconstr Surg 114:360-6. 2004
    ..Correcting overestimation of breast cancer risk in women who have prophylactic mastectomy may improve satisfaction with reconstruction following prophylactic mastectomy...
  61. ncbi BRCA1 and BRCA2: 1994 and beyond
    Steven A Narod
    Centre for Research on Women s Health, Sunnybrook and Womens College Health Sciences Center, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    Nat Rev Cancer 4:665-76. 2004
    ..The ability to translate this knowledge into novel treatments, however, remains elusive...
  62. ncbi Heterozygosity for the BLM(Ash) mutation and cancer risk
    Sean P Cleary
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer Res 63:1769-71. 2003
    ....
  63. ncbi Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy
    Kelly A Metcalfe
    The Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    J Natl Cancer Inst 94:1564-9. 2002
    ..We compared the perceptions of breast cancer risk among women who had previously undergone prophylactic bilateral mastectomy with objective estimates of their breast cancer risk...
  64. ncbi Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation
    Elzbieta Kowalska
    Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada, M5G 1N8
    Cancer Epidemiol Biomarkers Prev 14:1302-6. 2005
    ..40 versus 0.39). Oral selenium is a good candidate for chemoprevention in women who carry a mutation in the BRCA1 gene...
  65. ncbi Prophylactic bilateral mastectomy: patterns of practice
    Kelly A Metcalfe
    The Centre for Research in Women s Health, Toronto, Ontario, Canada
    Cancer 95:236-42. 2002
    ..We conducted a population-based study to review the indications for, and patterns of practice of prophylactic mastectomy in Ontario, Canada, since 1991...
  66. ncbi Cancer incidence in a population of Jewish women at risk of ovarian cancer
    Alexander Liede
    Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    J Clin Oncol 20:1570-7. 2002
    ..To evaluate the incidence and clinical characteristics of ovarian and other cancers in a cohort of women at risk of developing ovarian cancer...
  67. doi Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer
    Taryn Becker
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Am Geriatr Soc 60:1761-7. 2012
    ..To review data from randomized controlled trials (RCTs) that evaluate adverse bone outcomes in older women using aromatase inhibitors (AIs) for early-stage hormone receptor-positive breast cancer...
  68. pmc Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1
    Ian Harley
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, ON, Canada
    Gynecol Oncol 109:384-7. 2008
    ..We sought to establish whether or not this polymorphic variant also predisposes to ovarian cancer...
  69. ncbi Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective
    Steven A Narod
    Women s College Research Institute, University of Toronto, Canada
    Salud Publica Mex 51:s191-6. 2009
    ..It is important that a genetic testing service be a multi-disciplinary effort with co-ordinated follow-up...
  70. ncbi The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study
    Mario E Beiner
    Centre for Research in Women s Health, 790 Bay Street, Toronto, ON, Canada M5G 1N8
    Gynecol Oncol 104:7-10. 2007
    ..To evaluate the risk of endometrial cancer in women who carry a deleterious mutation in the BRCA1 or BRCA2 genes...
  71. doi Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women
    Kelly A Metcalfe
    Lawrence S Bloomberg, Faculty of Nursing and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 28:387-91. 2010
    ..To date, population screening in this population has not been suggested. However, this may be rational. Little is known about the appropriateness of testing guidelines for the Jewish population or the level of interest in testing...
  72. doi Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers
    Joanne Kotsopoulos
    Women s College Research Institute, 790 Bay Street, Toronto, Ontario, Canada
    Cancer Causes Control 21:679-87. 2010
    ..These results provide evidence for a possible protective effect of selenium against BRCA1-associated breast cancers...
  73. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  74. doi Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, Canada
    Breast Cancer Res Treat 112:585-93. 2008
    ..Individual variation in the genes involved in the transport of folate, or its metabolism, may affect risk, or may modify the association between folate and breast cancer risk...
  75. pmc Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer
    Mohammad R Akbari
    Women s College Research Institute, Women s College Hospital, University of Toronto, Toronto, Canada
    Cancer Epidemiol 37:424-7. 2013
    ..Data has suggested that HOXB13 expression levels are decreased in colorectal cancer (CRC) cell lines indicating this gene may be involved in colorectal tumourigenesis...
  76. doi BRCA1 haploinsufficiency: consequences for breast cancer
    Leonardo Salmena
    Women s College Research Institute, University of Toronto, Toronto, ON, M5G 1N8, Canada
    Womens Health (Lond Engl) 8:127-9. 2012
    ..They conclude that BRCA1 is a haploinsufficient tumor suppressor gene, which when lost through inheritance, increases a cell's susceptibility to acquire further mutations...
  77. ncbi Mutation screening using fluorescence multiplex denaturing gradient gel electrophoresis (FMD): detecting mutations in the BRCA1 gene
    Shiyu Zhang
    The Centre for Research in Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario, M5G IN8, Canada
    Nat Protoc 1:3101-10. 2006
    ..It may also be adapted to screen other target genes and/or used in large-scale epidemiological studies...
  78. ncbi A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density
    Joe H Lai
    Centre for Research in Women s Health, University of Toronto, 8790 Bay Street, Toronto, Ontario, M5G 1N8 Canada
    Cancer Epidemiol Biomarkers Prev 13:573-82. 2004
    ....
  79. ncbi Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk
    Robert K Nam
    Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, MG 406 Toronto, Ontario, Canada, M4N 3M5
    Cancer Epidemiol Biomarkers Prev 14:1270-3. 2005
    ..Larger studies will be required to confirm this relationship...
  80. ncbi Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    J Clin Oncol 22:1055-62. 2004
    ..Thus, we estimated the degree of breast cancer risk reduction after surgery in women who carry these mutations...
  81. ncbi BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families
    Olga M Sinilnikova
    Plate forme Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon Centre Léon Bérard, Lyon Cedex 08, 69373, France
    Fam Cancer 5:15-20. 2006
    ....
  82. ncbi Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study
    William D Foulkes
    J Natl Cancer Inst 95:1640. 2003
  83. ncbi Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)
    Francesmary Modugno
    Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Cancer Causes Control 14:439-46. 2003
    ..To determine whether oral contraceptive (OC) use, childbearing, breastfeeding and tubal ligation differ between ovarian cancer cases with and without a BRCA1/2 mutation...
  84. ncbi Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    N Engl J Med 346:1616-22. 2002
    ..We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations...
  85. ncbi Hereditary ovarian cancer in Poland
    Janusz Menkiszak
    Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
    Int J Cancer 106:942-5. 2003
    ..It is important that mutation surveys be conducted in other countries prior to the introduction of national genetic screening programs...
  86. ncbi Re: On the use of familial aggregation in population-based case probands for calculating penetrance
    Harvey A Risch
    J Natl Cancer Inst 95:73-4; author reply 77-8. 2003
  87. ncbi Re: Cancer risks in BRCA1 carriers: time for the next generation of studies
    Harvey A Risch
    J Natl Cancer Inst 95:758. 2003
  88. ncbi BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines
    Maria Lourdes De Leon Matsuda
    Department of Surgery, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines
    Int J Cancer 98:596-603. 2002
    ..Germline mutations in the BRCA2 gene contribute more than mutations BRCA1 to breast cancer in the Philippines, due in large part to the presence of 2 common founder mutations...
  89. ncbi Improved survival in women with BRCA-associated ovarian carcinoma
    Ilana Cass
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center and University of California Los Angeles School of Medicine, Los Angeles, California 90048, USAA
    Cancer 97:2187-95. 2003
    ..The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma...
  90. pmc RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
    Am J Hum Genet 81:1186-200. 2007
    ..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...
  91. ncbi Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families
    Suzanna L Arcand
    The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
    Breast Cancer Res Treat 108:399-408. 2008
    ..In all, germline TP53 mutations were identified in two of 52 (3.8%) cancer families, suggesting that TP53 is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or ovarian cancer families of French Canadian descent...
  92. ncbi Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type
    William D Foulkes
    Departments of Oncology, Sir M B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Clin Cancer Res 10:2029-34. 2004
    ..The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied...
  93. ncbi Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations
    Murray Joseph Casey
    Department of Obstetrics and Gynecology, Creighton University School of Medicine and the Creighton Hereditary Cancer Institute, Creighton University Medical Center, 601 North 30th Street, Suite 4700, Omaha, NE 68131, USA
    Gynecol Oncol 97:457-67. 2005
    ....
  94. ncbi Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer
    Lori J Pierce
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 24:2437-43. 2006
    ..We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls...
  95. pmc Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
    Eitan Friedman
    The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Breast Cancer Res 8:R15. 2006
    ....
  96. ncbi Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families
    Henry T Lynch
    Department of Preventive Medicine and Public Health, Creighton University, 2500 California Plaza, Omaha, Nebraska 68178, USA
    Cancer Genet Cytogenet 165:91-7. 2006
    ..Despite these psychological consequences, carriers and noncarriers reported a positive attitude toward genetic testing...
  97. ncbi Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
    Carey A Cullinane
    City of Hope National Medical Center, Duarte, CA, USA
    Int J Cancer 117:988-91. 2005
    ..Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy...
  98. ncbi Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update
    Jacek Gronwald
    Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical Academy, Szczecin, Poland
    Int J Cancer 118:2281-4. 2006
    ..83; 95%CI, 0.24-2.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65)...
  99. pmc A common missense variant in BRCA2 predisposes to early onset breast cancer
    Bohdan Gorski
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
    Breast Cancer Res 7:R1023-7. 2005
    ..For a deleterious variant, one would expect a greater allele frequency in breast cancer cases than in ethnic-matched controls. In contrast, neutral polymorphic variants should be equally frequent in the two groups...
  100. ncbi Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland
    Jacek Gronwald
    International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
    Breast Cancer Res Treat 95:105-9. 2006
    ..BRCA1 carriers with late age of menarche, lower parity and long-term breast-feeding were less likely to develop breast cancer. Oral contraceptives protected against ovarian cancer...
  101. ncbi Direct-to-patient BRCA1 testing: the Twoj Styl experience
    Jacek Gronwald
    Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Polabska 4, 70 115, Szczecin, Poland
    Breast Cancer Res Treat 100:239-45. 2006
    ..We found this model of genetic testing and delivery of genetic information to be very efficient in a population in which founder mutations predominate. There is a need for similar studies in other populations...